Bristol-Myers Squibb Company (NYSE:BMY) is set to announce third quarter earning results on Thursday 5th November 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, BMY to report 3Q20 income of $ 1.49 per share.
For the full year, analysts anticipate top line of $ 41957.40 million, while looking forward to income of $ 6.27 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 40,500.00 million ~ $ 42,000.00 million, where as bottomline are predicted in a range of $ 6.10 ~ $ 6.25 per share
Click Here For More Historical Outlooks Of Bristol-Myers Squibb Company
Previous Quarter Performance
Bristol-Myers Squibb Company reported income for the second quarter of $ 1.63 per share, from the revenue of $ 10,129.00 million. The quarterly earnings gained 38.14 percent while revenues up 61.47 percent compared with the same quarter last year.
According to street consensus, BMY was expected to report 2Q20 income of $ 1.48 per share from revenue of $ 9970.78 million. The bottom line results beat street analysts by $ 0.15 or 10.14 percent, at the same time, top line results outshined analysts by $ 158.22 million or 1.59 percent.
Stock Performance
Shares of Bristol-Myers Squibb Company traded up $ 4.19 or 6.84 percent on Wednesday, reaching $ 65.43 with volume of 23.37 million shares. Bristol-Myers Squibb Company has traded high as $ 66.23 and has cracked $ 63.75 on the downward trend
The closing price of $ 65.43, representing a 33.83 % increase from the 52 week low of $ 45.76 and a 10.39 % decrease over the 52 week high of $ 68.34.
The company has a market capital of $ 147.47 billion and is part of the Healthcare sector and Drug Manufacturers – Major industry.
Recent Analyst recommendations
- On 19th October 2020, upgraded by Guggenheim to Buy from Neutral rating
- On 16th October 2020, maintained by JPMorgan Chase & Co. at Overweight rating, with $ 78.00 target price.
- On 29th September 2020, initiated by Berenberg Bank at Buy rating, with $ 73.00 target price.
- On 22nd September 2020, maintained by Raymond James at Outperform rating, with $ 78.00 target price.
Conference Call
Bristol-Myers Squibb Company will be hosting a conference call at 8:30 AM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.bms.com
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The companys products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
